問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital

Division of Cardiovascular Diseases

Division of Endocrinology

Far Eastern Memorial Hospital

Division of General Internal Medicine

Division of Endocrinology

更新時間：2025-09-23

王治元CHIH-YUAN WANG, CHIH-YUAN WANG
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王治元

List

31Cases

2024-01-16 - 2026-06-30

Phase III

Active
Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    CagriSemaTirzepatide

Participate Sites
7Sites

Recruiting7Sites

2024-09-30 - 2026-06-30

Phase II

Active
A Phase 2b dose-finding, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of BAY 3283142 on top of standard of care in reducing albuminuria in patients with chronic kidney disease

  • Condition/Disease

    chronic kidney disease

  • Test Drug

    tablets

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2012-06-01 - 2018-11-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2011-11-01 - 2020-02-28

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2008-10-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-01-01 - 2010-06-30

Phase III

Evaluation Dapagliflozin inhibitor and with Metformin and controls DPP-4 (Sitagliptin) and received unilateral Metformin Metformin therapy with poor glycemic control in diabetic adult still disease international efficacy and safety of 24 weeks after a second type, multi-center, Random assignment, parallel, double-blind, curative effect control group, phase III clinical trial.

  • Condition/Disease

    Patients with type 2 diabetes who still have poor blood sugar control after taking at least 1,500 mg of Metformin daily

  • Test Drug

    Dapagliflozin/placebo; Sitagliptin/placebo

Participate Sites
8Sites

Terminated8Sites

2017-10-01 - 2021-03-31

Phase II

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    CS02 Tablet

Participate Sites
13Sites

Recruiting2Sites

Terminated10Sites

陳清助
China Medical University Hospital-Taipei

未分科

陳涵栩
Taipei Veterans General Hospital

Division of Endocrinology

2014-12-30 - 2019-12-31

Phase III

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)

  • Condition/Disease

    major adverse cardiovascular event, MACE

  • Test Drug

    Epanova®

Participate Sites
7Sites

Terminated6Sites

江晨恩
Taipei Veterans General Hospital

賴文德
Kaohsiung Municipal Gangshan Hospital

未分科

2012-02-01 - 2015-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2008-03-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB